Renibus Therapeutics
Visit Website
Summary
Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients’ lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases.
Renibus’ first-in-a-new class lead program is RBT-1 (stannic protoporfin /iron sucrose), a single dose IV drug that is given over approximately 2 hours, 24-48 hours prior to patients undergoing elective cardiac and or valve surgery. RBT-1 is a preconditioning agent with anti-inflammatory and antioxidant properties, which is being studied in the Phase 3 PROTECT trial to reduce the risk of post operative complications following cardiothoracic surgery (CABG and/or heart valve). The drug has received FDA Breakthrough and Fast Track Designations.
Educational Links:
Explore Renibus’ fact sheet for a concise overview, including sections on ‘About Us,’ ‘Quick Facts,’ ‘Leadership Team,’ ‘Board of Directors,’ and our robust ‘Product Portfolio.
RBT-1 Fact Sheet
Learn more about Renibus’ lead product, RBT-1, a first-in-a-new-class pharmacologic preconditioning agent, to reduce the risk of post-operative complications and improve patient outcomes following cardiothoracic surgery.
Media Articles
Read articles featuring Renibus in leading publications such as Endpoints News and Fierce Biotech showcasing some of our recent accomplishments.
Publications
Review the recent publication in E-Clinical Medicine, part of The Lancet Discovery Science, of the results from our Phase 2 study evaluating RBT-1.
Press Releases
Stay updated with our latest corporate milestones, key achievements, and recent announcements by exploring our latest press releases.
Social Media
Connect with us on social media and stay up-to-date with how we're transforming the cardio-renal disease treatment paradigm.
